<DOC>
	<DOCNO>NCT03026166</DOCNO>
	<brief_summary>The purpose multicenter , Phase 1/2 , open-label , study assess safety efficacy rovalpituzumab tesirine administer combination nivolumab nivolumab ipilimumab participant extensive-stage small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Rovalpituzumab Tesirine Administered Combination With Nivolumab With Without Ipilimumab Adults With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Participants histologically cytologically confirm extensivestage small cell lung cancer ( SCLC ) progressive disease least one platinumbased chemotherapeutic regimen evaluable measurable disease Eastern Cooperative Oncology Group ( ECOG ) 01 Adequate hematologic , hepatic , renal function Has active , know , suspect autoimmune disease Had prior exposure immunooncology pyrrolobenzodiazepine ( PBD ) base drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nivolumab</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Rovalpituzumab tesirine</keyword>
	<keyword>Cancer</keyword>
	<keyword>Extensive-Stage Small Cell Lung Cancer</keyword>
</DOC>